Cellular senescence, a process where cells stop dividing and secrete harmful factors, contributes to age-related endocrine dysfunction. Senolytics remove senescent cells, while senomorphics reduce their harmful secretions. These therapies may alleviate diseases like diabetes, osteoporosis, and cancer. Over 30 clinical trials have tested these agents, showing promise but requiring further study. Senescent cells accumulate in endocrine organs, impairing function and contributing to disorders like diabetes and osteoporosis. Targeting senescent cells offers a novel approach to treat endocrine diseases, potentially improving existing therapies. Senescent cells are marked by specific proteins and signals, and their accumulation is linked to aging. Senolytics and senomorphics are being explored as treatments for various conditions, including endocrine disorders. Research indicates that senescent cells in the adrenal, thyroid, and other endocrine organs may contribute to dysfunction. Therapies targeting senescent cells, such as senolytics and senomorphics, are being investigated for their potential to improve healthspan and treat age-related diseases. The role of cellular senescence in endocrine dysfunction is increasingly understood, and targeting it may offer new therapeutic strategies.Cellular senescence, a process where cells stop dividing and secrete harmful factors, contributes to age-related endocrine dysfunction. Senolytics remove senescent cells, while senomorphics reduce their harmful secretions. These therapies may alleviate diseases like diabetes, osteoporosis, and cancer. Over 30 clinical trials have tested these agents, showing promise but requiring further study. Senescent cells accumulate in endocrine organs, impairing function and contributing to disorders like diabetes and osteoporosis. Targeting senescent cells offers a novel approach to treat endocrine diseases, potentially improving existing therapies. Senescent cells are marked by specific proteins and signals, and their accumulation is linked to aging. Senolytics and senomorphics are being explored as treatments for various conditions, including endocrine disorders. Research indicates that senescent cells in the adrenal, thyroid, and other endocrine organs may contribute to dysfunction. Therapies targeting senescent cells, such as senolytics and senomorphics, are being investigated for their potential to improve healthspan and treat age-related diseases. The role of cellular senescence in endocrine dysfunction is increasingly understood, and targeting it may offer new therapeutic strategies.